Biohit Oyj Past Earnings Performance

Past criteria checks 3/6

Biohit Oyj has been growing earnings at an average annual rate of 59.4%, while the Medical Equipment industry saw earnings growing at 1.9% annually. Revenues have been growing at an average rate of 9.6% per year. Biohit Oyj's return on equity is 15.3%, and it has net margins of 11.8%.

Key information

59.4%

Earnings growth rate

59.4%

EPS growth rate

Medical Equipment Industry Growth-9.5%
Revenue growth rate9.6%
Return on equity15.3%
Net Margin11.8%
Next Earnings Update12 Feb 2025

Recent past performance updates

No updates

Recent updates

No updates

Revenue & Expenses Breakdown

How Biohit Oyj makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

LSE:0DRP Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2414240
31 Mar 2414240
31 Dec 2313240
30 Sep 2312140
30 Jun 2311140
31 Mar 2311140
31 Dec 2211140
30 Sep 2211140
30 Jun 2211140
31 Mar 2210040
31 Dec 219-130
30 Sep 219-230
30 Jun 218-230
31 Mar 218-330
31 Dec 207-330
30 Sep 208-330
30 Jun 208-330
31 Mar 209-230
31 Dec 1910-130
30 Sep 1910-230
30 Jun 1910-230
31 Mar 1910-230
31 Dec 1810-230
30 Sep 1810-230
30 Jun 1810-230
31 Mar 189230
31 Dec 179630
30 Sep 17964-1
30 Jun 17864-1
31 Mar 17814-1
31 Dec 168-350
30 Sep 167-451
30 Jun 166-452
31 Mar 167-352
31 Dec 156-352
30 Sep 156-352
30 Jun 156-452
31 Mar 155-452
31 Dec 144-452
30 Sep 144-552
30 Jun 144-562
31 Mar 144-671

Quality Earnings: 0DRP has a high level of non-cash earnings.

Growing Profit Margin: 0DRP's current net profit margins (11.8%) are higher than last year (9.7%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 0DRP has become profitable over the past 5 years, growing earnings by 59.4% per year.

Accelerating Growth: 0DRP's earnings growth over the past year (50%) is below its 5-year average (59.4% per year).

Earnings vs Industry: 0DRP earnings growth over the past year (50%) exceeded the Medical Equipment industry 39.9%.


Return on Equity

High ROE: 0DRP's Return on Equity (15.3%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 04:17
End of Day Share Price 2025/01/02 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Biohit Oyj is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Antti SiltanenInderes Oy